| 67.59 -3.36 (-4.74%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 83.52 | 1-year : | 97.55 |
| Resists | First : | 71.51 | Second : | 83.52 |
| Pivot price | 67.7  |
|||
| Supports | First : | 64.96 | Second : | 60.91 |
| MAs | MA(5) : | 69.46 |
MA(20) : | 66.72 |
| MA(100) : | 64.57 |
MA(250) : | 71.33 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 81.5 |
D(3) : | 84.5 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 107.37 | Low : | 47.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACLX ] has closed above bottom band by 48.4%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.44 - 71.82 | 71.82 - 72.14 |
| Low: | 66.07 - 66.48 | 66.48 - 66.83 |
| Close: | 66.92 - 67.61 | 67.61 - 68.21 |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Thu, 17 Jul 2025
There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Price - 富途牛牛
Thu, 17 Jul 2025
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment - TipRanks
Tue, 15 Jul 2025
Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha
Fri, 11 Jul 2025
We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate - simplywall.st
Wed, 09 Jul 2025
How might ACLX's 2025 Q1 EPS forecast affect strategies? - AInvest
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 102 (%) |
| Shares Short | 6,240 (K) |
| Shares Short P.Month | 7,130 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.57 |
| Profit Margin | -211.5 % |
| Operating Margin | -847.6 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -35.6 % |
| Qtrly Rev. Growth | -79.4 % |
| Gross Profit (p.s.) | -1.8 |
| Sales Per Share | 1.39 |
| EBITDA (p.s.) | -3.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -22.61 |
| PEG Ratio | 0 |
| Price to Book value | 8.92 |
| Price to Sales | 48.49 |
| Price to Cash Flow | -32.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|